LUNDBECK BEGINS PHASE I TRIAL OF LU AA34893 FOR DEPRESSION

Lundbeck has initiated Phase I clinical trials with its pharmaceutical candidate Lu AA34893 to investigate the tolerability and pharmacokinetic profile of the compound in humans as a treatment for depression.

Lu AA34893 was selected as a development candidate based on its convincing effect in preclinical animal models suggesting a potential to improve the treatment of depression and anxiety disorders.